Mechanisms of atherothrombosis in chronic obstructive pulmonary disease

International Journal of COPD

Volumn 3, Issue 1, 2008, Pages 89-96

  Fimognari, Filippo Luca ^a,b   Scarlata, Simone ^a   Conte, Maria Elisabetta ^a   Incalzi, Raffaele Antonelli ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b Leopoldo Parodi Delfino Hospital   (Italy)

Author keywords

Atherothrombosis; Cardiovascular risk; COPD; Mortality

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; C REACTIVE PROTEIN; CORTICOSTEROID; FLUTICASONE; LIPID; LOW DENSITY LIPOPROTEIN; NEUROHORMONE; PLACEBO; SALMETEROL; SIMVASTATIN; THROMBOXANE;

ARTERY THROMBOSIS; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; HUMAN; HYPERCOAGULABILITY; HYPOXIA; INFLAMMATION; METABOLIC SYNDROME X; MORTALITY; NONHUMAN; OXIDATIVE STRESS; OXYGEN THERAPY; PATHOGENESIS; PREVALENCE; PROTEIN BLOOD LEVEL; REVIEW; RISK FACTOR; THROMBOCYTE ACTIVATION;

ATHEROSCLEROSIS; HUMANS; OXIDATIVE STRESS; PLATELET ACTIVATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; THROMBOSIS;

EID: 42149172369     PISSN: 11769106     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Afessa B, Morales IJ, Scanlon PD, et al. 2002. Prognostic factors, clinical course, and hospital outcome of patients with chronic obstructive pulmonary disease admitted to an intensive care unit for acute respiratory failure. Crit Care Med, 30:1610-15.
2. Alessandri C, Basili S, Violi F, et al. 1994. Hypercoagulability state in patients with chronic obstructive pulmonary disease. Chronic Obstructive Bronchitis and Haemostasis Group. Thromb Haemost, 72:343-6.
3. Andreas S, Anker SD, Scanlon PD, et al. 2005. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest, 128:3618-24.
4. Ashitani J, Mukae H, Arimura Y, et al. 2002. Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease. Intern Med, 41:181-5.
5. Basili S, Ferroni P, Vieri M, et al. 1999. Lipoprotein(a) serum levels in patients affected by chronic obstructive pulmonary disease. Atherosclerosis, 147:249-52.
6. Berliner JA, Heinecke JW. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med, 20:707-27.
7. Boots AW, Haenen GR, Bast A. 2003. Oxidant metabolism in chronic obstructive pulmonary disease. Eur Respir J Suppl, 46:14s-27s.
8. Borovikova LV, Ivanova S, Zhang M, et al. 2000. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature, 405:458-62.
9. Calverley PM, Walker P. 2003. Chronic obstructive pulmonary disease. Lancet, 362:1053-61.
10. Calverley PM, Anderson JA, Celli B, et al; TORCH investigators. 2007. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med, 356:775-89.
11. Carpagnano GE, Kharitonov SA, Foschino-Barbaro MP, et al. 2004. Supplementary oxygen in healthy subjects and those with COPD increases oxidative stress and airway inflammation. Thorax, 59:1016-19.
12. Cordova C, Musca A, Violi F, et al. 1985. Platelet hyperfunction in patients with chronic airways obstruction. Eur J Respir Dis, 66:9-12.
13. Danesh J, Collins R, Appleby P, et al. 1998. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA, 279:1477-82.
14. Davì G, Basili S, Vieri M, et al. 1997. Enhanced thromboxane biosynthesis in patients with chronic obstructive pulmonary disease. The Chronic Obstructive Bronchitis and Haemostasis Study Group. Am J Respir Crit Care Med, 156:1794-9.
15. Dekhuijzen PN, Aben KK, Dekker I, et al. 1996. Increased exhalation of hydrogen peroxide in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 154:813-16.
16. Delanty N, Reilly M, Pratico D, et al. 1996. 8-Epi PGF2 alpha: specific analysis of an isoeicosanoid as an index of oxidant stress in vivo. Br J Clin Pharmacol, 42:15-19.
17. Devaraj S, Hirany SV, Burk RF, et al. 2001. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem, 47:1974-9.
18. Eickelberg O, Roth M, Lorx R, et al. 1999. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem, 274:1005-10.
19. Eikelboom JW, Hirsh J, Weitz JI, et al. 2002. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation, 105:1650-5.
20. Engstrom G, Wollmer P, Hedblad B, et al. 2001. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmo, Sweden. Circulation, 103:3086-91.
21. Esmon CT. 2000. Does inflammation contribute to thrombotic events? Haemostasis, 30(Suppl 2):34-40.
22. Fimognari FL, Pasqualetti P, Moro L, et al. 2007. The association between metabolic syndrome and restrictive ventilatory dysfunction in older persons. J Gerontol A Biol Sci Med, 62:760-5.
23. Fimognari FL, Piccirillo G, Lama J, et al. 1996. Associated daily biosynthesis of cortisol and thromboxane A2: a preliminary report. J Lab Clin Med, 128:115-21.
24. Ford ES, Mannino DM. 2004. Prospective association between lung function and the incidence of diabetes: findings from the National Health and Nutrition Examination Survey Epidemiologic Follow-up Study. Diabetes Care, 27:2966-70.
25. Gan WQ, Man SF, Senthilselvan A, et al. 2004, Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax, 59:574-80.
26. Halbert RJ, Natoli JL, Gano A, et al. 2006. Global burden of COPD: systematic review and meta-analysis. Eur Respir J, 28:523-32.
27. Hansell AL, Walk JA, Soriano JB. 2003. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur Respir J, 22:809-14.
28. Hjemdahl P, Larsson PT, Wallen NH. 1991. Effects of stress and beta-blockade on platelet function. Circulation, 84:VI44-61.
29. Hjemdahl P, Chronos NA, Wilson DJ, et al. 1994. Epinephrine sensitizes human platelets in vivo and in vitro as studied by fibrinogen binding and P-selectin expression. Arterioscler Thromb, 14:77-84.
30. Hole DJ, Watt GC, Davey-Smith G, et al. 1996. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ, 313:711-15.
31. Hsia CC, Raskin P. 2005. The diabetic lung: relevance of alveolar microangiopathy for the use of inhaled insulin. Am J Med, 118:205-11.
32. Huiart L, Ernst P, Ranouil X, et al. 2005. Low-dose inhaled corticosteroids and the risk of acute myocardial infarction in COPD. Eur Respir J, 25:634-9.
33. Joppa P, Petrasova D, Stancak B, et al. 2006. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest, 130:326-33.
34. Larsson PT, Wallen NH, Hjemdahl P. 1994. Norepinephrine-induced human platelet activation in vivo is only partly counteracted by aspirin. Circulation, 89:1951-7.
35. Lawlor DA, Ebrahim S, Smith GD. 2004. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women's Heart and Health Study. Diabetologia, 47:195-203.
36. Li M, Zheng C, Sato T, et al. 2004. Vagal nerve stimulation markedly improves long-term survival after chronic heart failure in rats. Circulation, 109:120-4.
37. Libby P, Simon DI. 2001. Inflammation and thrombosis: the clot thickens. Circulation, 103:1718-20.
38. Lofdahl CG, Postma D, Pride N. 2005. Does inhaled budesonide protect against cardio-ischemic events in mild-moderate COPD: a post-hoc evaluation of the EUROSCOP Study [Abstract]. European Respiratory Society Conference, Copenhagen 2005.
39. Macie C, Wooldrage K, Manfreda J, et al. 2006. Inhaled corticosteroids and mortality in COPD. Chest, 130:640-6.
40. Man SF, Connett JE, Anthonisen NR, et al. 2006. C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax, 61:849-53.
41. Meier CR, Jick SS, Derby LE, et al. 1998. Acute respiratory-tract infections and risk of first-time acute myocardial infarction. Lancet, 351:1467-71.
42. Nowak D, Kasielski M, Antczak A, et al. 1999. Increased content of thiobarbituric acid-reactive substances and hydrogen peroxide in the expired breath condensate of patients with stable chronic obstructive pulmonary disease: no significant effect of cigarette smoking. Respir Med, 93:389-96.
43. 2 and thiobarbituric acid reactive substances (TBARs) by healthy subjects. Free Radic Biol Med, 30:178-86.
44. Ogawa S, Shreeniwas R, Brett J, et al. 1990. The effect of hypoxia on capillary endothelial cell function: modulation of barrier and coagulant function. Br J Haematol, 75:517-24.
45. Pasceri V, Willerson JT, Yeh ET. 2000. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation, 102:2165-8.
46. Patrono C. 1990. Thromboxane synthesis inhibitors and receptor antagonists. Thromb Res Suppl, 11:15-23.
47. Patrono C, Coller B, FitzGerald GA, et al. 2004. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126:234S-264S.
48. Patrono C, Patrignani P, Rocca B, et al. 1995. Characterization of biochemical and functional effects of antiplatelet drugs as a key to their clinical development. Thromb Haemost, 74:396-400.
49. Pinto-Plata VM, Mullerova H, Toso JF, et al. 2006. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax, 61:23-8.
50. Ponicke K, Sternitzky R, Mest HJ. 1987. Stimulation of aggregation and thromboxane A2 formation of human platelets by hypoxia. Prostaglandins Leukot Med, 29:49-59.
51. Praticò D, Basili S, Vieri M, et al. 1998. Chronic obstructive pulmonary disease is associated with an increase in urinary levels of isoprostane F2alpha-III, an index of oxidant stress. Am J Respir Crit Care Med, 158:1709-14.
52. Rabinovich RA, Figueras M, Ardite E, et al. 2003. Increased tumour necrosis factor-alpha plasma levels during moderate-intensity exercise in COPD patients. Eur Respir J, 21:789-94.
53. Rana JS, Mittleman MA, Sheikh J, et al. 2004. Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care, 27:2478-84.
54. Rolin S, Masereel B, Dogne JM. 2006. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol, 533:89-100.
55. Russo A, De Luca M, Vigna C, et al. 1999. Central pulmonary artery lesions in chronic obstructive pulmonary disease: A transesophageal echocardiography study. Circulation, 100:1808-15.
56. Scandinavian Simvastatin Survival Study Group 1994. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet, 344:1383-9.
57. Scalvini S, Porta R, Zanelli E, et al. 1999. Effects of oxygen on autonomic nervous system dysfunction in patients with chronic obstructive pulmonary disease. Eur Respir J, 13:119-24.
58. Sin DD, Lacy P, York E, et al. 2004. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 170:760-5.
59. Sin DD, Wu L, Anderson JA, et al. 2005a. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 60:992-7.
60. Sin DD, Wu L, Man SF. 2005b. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest, 127:1952-9.
61. Takabatake N, Nakamura H, Abe S, et al. 2000. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 161:1179-84.
62. Tamaoki J, Kondo M, Nakata J, et al. 2000. Effect of a thromboxane A(2) antagonist on sputum production and its physicocheniical properties in patients with mild to moderate asthma. Chest, 118:73-9.
63. Truelsen T, Prescott E, Lange P, et al. 2001. Lung function and risk of fatal and non-fatal stroke. The Copenhagen City Heart Study. Int J Epidemiol, 30:145-51.
64. van Helvoort HA, Heijdra YF, Heunks LM, et al. 2006. Supplemental oxygen prevents exercise-induced oxidative stress in muscle-wasted patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med, 173:1122-9.
65. Vestbo J. 2004. The TORCH (towards a revolution in COPD health) survival study protocol. Eur Respir J, 24:206-10.
66. Wedzicha JA, Seemungal TA, MacCallum PK, et al. 2000. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost, 84:210-15.
67. Wedzicha JA, Syndercombe-Court, Tan KC. 1991. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax, 46:504-7.
68. Weitzenblum E, Hirth C, Ducolone A, et al. 1981. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax, 36:752-8.
69. Woiciechowsky C, Asadullah K, Nestler D, et al. 1998. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. Nat Med, 4:808-13.
70. Xie M, Wang Z. 1998. [Prethrombotic state in patients with chronic obstructive pulmonary disease and treatment with heparin]. Hua Xi Yi Ke Da Xue Xue Bao, 29:411-14.
71. Zoppini G, Targher G, Zamboni C, et al. 2006. Effects of moderate-intensity exercise training on plasma biomarkers of inflammation and endothelial dysfunction in older patients with type 2 diabetes. Nutr Metab Cardiovasc Dis, 16:543-9.
72. Zureik M, Benetos A, Neukirch C, et al. 2001. Reduced pulmonary function is associated with central arterial stiffness in men. Am J Respir Crit Care Med, 164:2181-5.